Porcine Dermatitis Nephropathy Syndrome (PDNS)

Porcine Dermatitis Nephropathy Syndrome, commonly known as PDNS, is a sporadic disease of pigs characterized by the combination of distinctive skin lesions and severe kidney disease. The condition is classified as an immune-mediated disease, with the kidney damage resulting from deposition of immune complexes in the glomeruli and blood vessels, leading to a type III hypersensitivity reaction. This immune dysregulation is strongly associated with infection by Porcine Circovirus type 2, which has become endemic in swine populations worldwide. The characteristic clinical presentation combines raised, purple-red skin lesions with progressive kidney failure, creating a distinctive syndrome that experienced producers and veterinarians can often recognize visually.

PDNS affects swine operations globally, with cases reported from all major pig-producing regions. The condition occurs sporadically rather than as epidemics, typically affecting individual animals or small clusters within herds where PCV2 is endemic. While morbidity at the herd level is generally low, usually affecting less than one percent of the population, case fatality rates in clinically affected pigs are high, often exceeding fifty percent. The condition primarily affects growing and finishing pigs between eight and sixteen weeks of age, though cases in older pigs and even adult breeding animals have been documented.

The economic and welfare impact of PDNS extends beyond direct mortality. Clinically affected pigs suffer significant illness with skin lesions that may be painful and kidneys that progressively fail, causing uremia and systemic malaise. The unpredictable, sporadic nature of the condition creates uncertainty for producers who cannot predict which animals will be affected. PDNS is recognized as part of the broader Porcine Circovirus Associated Disease complex, and its presence may indicate suboptimal PCV2 control within a herd even when the syndrome itself causes limited direct losses. The visible skin lesions can cause market concerns and condemnation at slaughter.

Treatability of PDNS is limited because there is no specific therapy for the underlying immune-mediated damage. Supportive care including anti-inflammatory medications, fluid support, and nursing care may help some mildly affected animals recover, but severely affected pigs typically do not respond to treatment and often die or require euthanasia. Prevention through PCV2 vaccination and reduction of cofactors that trigger immune dysregulation offers more promise than treating established cases. Understanding PDNS as part of the broader PCV2-associated disease complex helps frame prevention efforts within comprehensive herd health management.

The primary cause of PDNS is believed to be immune dysregulation associated with Porcine Circovirus type 2 infection. PCV2 is a small DNA virus that has become virtually ubiquitous in swine populations worldwide. While most PCV2-infected pigs remain clinically normal or develop only mild disease, a subset develop severe immune-mediated conditions including PDNS. The mechanism involves formation of antigen-antibody immune complexes that deposit in blood vessel walls and kidney glomeruli, triggering inflammatory damage through complement activation and neutrophil recruitment. This type III hypersensitivity reaction damages tissues through friendly fire of the immune system rather than direct viral destruction.

Genetic predisposition to PDNS has not been definitively established, but individual variation in immune response likely influences which PCV2-infected pigs develop the syndrome. Some studies have suggested that certain genetic lines may have higher susceptibility to PCV2-associated diseases in general. The immune system's handling of viral infection and immune complex formation varies between individuals based on their genetic background, and these differences may partially explain why only sporadic individuals develop PDNS in enzootically infected herds where most pigs remain healthy.

Environmental and management factors serve as important cofactors in PDNS development. High stocking density, poor ventilation, mixing of pigs from different sources, and other stressors that challenge the immune system appear to increase the likelihood of clinical disease expression in PCV2-infected pigs. Concurrent infections with other pathogens such as Porcine Reproductive and Respiratory Syndrome virus, Mycoplasma hyopneumoniae, or bacterial pathogens may trigger or exacerbate immune dysregulation. Inadequate nutrition, particularly deficiencies affecting immune function, may contribute to susceptibility. Environmental conditions that impair respiratory health increase overall disease pressure.

Risk factors for developing PDNS include age between eight and sixteen weeks when maternal immunity wanes and active PCV2 infection is common, presence of concurrent infections or immune challenges, high viral loads of PCV2 in the environment or individual animals, absence of PCV2 vaccination, and management practices that create immune stress. Pigs from herds with endemic PRRS or other concurrent viral diseases appear to be at higher risk. Newly introduced pigs mixing with resident populations, weaning stress, and transport stress are recognized triggers for PCV2-associated disease expression including PDNS.

The pathophysiology of PDNS centers on immune complex deposition and resultant vasculitis and glomerulonephritis. Circulating immune complexes containing viral antigens and antibodies deposit in the walls of small blood vessels throughout the body and particularly in the renal glomeruli. This triggers complement cascade activation and recruitment of inflammatory cells, causing necrotizing vasculitis with characteristic vessel wall damage. In the kidneys, glomerulonephritis with fibrinoid necrosis develops, impairing kidney function. The skin lesions result from vasculitis in the dermal blood vessels, causing hemorrhage and necrosis visible as the characteristic purple-red macules and papules. Widespread vasculitis may affect other organs including lungs and lymph nodes.

Early warning signs of PDNS may be subtle before the characteristic skin lesions and severe systemic illness develop. Affected pigs may show mild depression and decreased feed intake in the early stages. Slight reduction in growth rate compared to pen mates may be noted by observant producers. Some pigs may appear slightly stiff or reluctant to move actively, potentially reflecting early kidney discomfort or joint involvement from vasculitis. Fever may be present in early stages. These nonspecific signs are easily overlooked until the distinctive skin lesions appear and make the condition recognizable.

The hallmark symptom of PDNS is the characteristic skin lesions that give the condition its name. These lesions typically begin as raised, red macules that rapidly progress to become dark purple-red papules and plaques. The lesions have a distinctive appearance often described as target or bullseye lesions, with a central dark area surrounded by a red rim. Lesions occur most commonly on the hindquarters, perineal region, and rear legs, though they may spread to involve the ventral abdomen, ears, and forelimbs in severe cases. The lesions may coalesce to form larger areas of affected skin. Unlike some other pig skin conditions, PDNS lesions typically do not cause intense itching, and affected pigs do not excessively rub or scratch.

Behavioral changes in pigs with PDNS reflect the systemic nature of the illness. Affected pigs become progressively depressed and lethargic as the disease progresses. They separate from pen mates and may lie apart from the group. Appetite decreases and may progress to complete anorexia in severe cases. Movement becomes reluctant and slow, with affected pigs showing stiff gait or unwillingness to rise. Social interactions cease, and affected pigs become unresponsive to feeding activities or other stimuli that would normally elicit response. In severe cases, pigs may become recumbent and unable or unwilling to stand.

Physical signs beyond the skin lesions include progressive weight loss as the disease progresses, often becoming apparent over days to weeks. Pale mucous membranes indicate anemia, which commonly accompanies the kidney disease. Dependent edema may develop in the limbs and ventral body as kidney function declines and protein is lost through damaged glomeruli. Dehydration may be evident despite water availability. Respiratory rate may increase with anemia or lung involvement. Body temperature is variable, with fever possible in early stages and normal or subnormal temperature later. Examination may reveal swollen, firm lymph nodes in some cases.

Symptom progression in PDNS typically follows a pattern of worsening over days to weeks. Initial nonspecific illness gives way to development of characteristic skin lesions, which may continue to appear and enlarge over several days. Systemic illness intensifies with progressive depression, anorexia, and weight loss. As kidney failure advances, uremic signs including oral ulceration, further depression, and neurological abnormalities may develop. Severely affected pigs deteriorate to recumbency and death over a period of one to three weeks from onset in most fatal cases. A minority of affected pigs, particularly those with milder presentations, may stabilize and slowly recover.

Emergency symptoms requiring immediate veterinary evaluation include rapid progression of skin lesions with severe systemic illness, marked depression or recumbency, complete anorexia, signs of severe uremia including neurological abnormalities or oral ulceration, and multiple animals developing characteristic lesions simultaneously suggesting a potential outbreak. While PDNS typically affects individual animals sporadically, clusters of cases warrant herd-level investigation and intervention. Severely affected animals that are deteriorating despite supportive care should be evaluated for humane euthanasia to prevent prolonged suffering.

Clinical examination for PDNS begins with recognition of the characteristic skin lesions in a pig of appropriate age with compatible systemic illness. The distinctive appearance of the dark purple-red raised lesions, particularly on the hindquarters and perineum, combined with depression, weight loss, and signs of kidney disease, creates a clinical picture that experienced clinicians can often diagnose presumptively. Physical examination should assess the distribution and character of skin lesions, evaluate for signs of systemic illness including depression and wasting, and look for signs of kidney failure such as edema and pale mucous membranes. Rectal temperature and basic vital parameters should be recorded.

Diagnostic tests for PDNS confirmation include bloodwork, urinalysis, and ideally histopathology of affected tissues. Serum biochemistry reveals azotemia with elevated blood urea nitrogen and creatinine reflecting kidney dysfunction. Hypoalbuminemia may be present from urinary protein loss through damaged glomeruli. Complete blood count often shows anemia that may be normocytic normochromic or regenerative depending on chronicity. Urinalysis demonstrates proteinuria reflecting glomerular damage, often with low specific gravity indicating impaired concentration ability. PCV2 serology and PCR testing can confirm viral association. Skin biopsy demonstrates necrotizing vasculitis with fibrinoid vessel wall necrosis and inflammatory infiltrates. Kidney biopsy or necropsy samples show characteristic glomerulonephritis with fibrinoid necrosis and immune complex deposition demonstrable by immunohistochemistry.

Differential diagnosis for PDNS must consider other causes of skin lesions and kidney disease in pigs. Erysipelas causes diamond-shaped skin lesions but typically with different distribution, acute fever, and without primary kidney involvement. Classical swine fever and African swine fever cause hemorrhagic skin lesions but are accompanied by more widespread hemorrhage and high mortality, and must be ruled out in any suspicious case given their reportable status. Greasy pig disease from Staphylococcus hyicus causes skin disease but with greasy, scaly lesions rather than the hemorrhagic papules of PDNS. Drug reactions can cause skin lesions with systemic illness. Other causes of glomerulonephritis and kidney failure must be considered when kidney disease predominates over skin manifestations.

Herd-level diagnostics become important when PDNS cases increase beyond typical sporadic occurrence or when optimizing PCV2 control is desired. Population serology for PCV2 helps assess viral dynamics and timing of infection relative to vaccination. Evaluation of concurrent disease status, particularly PRRS and Mycoplasma hyopneumoniae status, identifies cofactors that may be triggering clinical expression. Review of vaccination protocols, timing of interventions, and management practices identifies opportunities for improvement. Necropsy of affected animals with comprehensive histopathology provides definitive diagnostic confirmation and may reveal concurrent conditions. Herd investigation helps distinguish PDNS from other conditions that might affect multiple animals, particularly the foreign animal diseases that must be considered with hemorrhagic skin lesions.

Emergency and immediate treatment for PDNS is largely supportive since no specific therapy addresses the underlying immune-mediated pathology. Affected pigs should be moved to hospital pens with reduced stocking density, comfortable bedding, and easy access to feed and water. Anti-inflammatory medications may help reduce the inflammatory component of the disease, though response is variable. Non-steroidal anti-inflammatory drugs are commonly used given their accessibility and familiarity, with appropriate attention to withdrawal times in food animals. Corticosteroids have been used in some cases to modulate the immune response, though evidence for efficacy is limited and concerns about immunosuppression in virally-infected animals temper enthusiasm for this approach.

Medical management of PDNS beyond initial supportive care involves ongoing nursing care and symptomatic treatment. Fluid therapy, whether oral or parenteral, helps maintain hydration and support kidney function. Nutritional support is important, with palatable, easily digestible feeds offered to encourage intake in animals with diminished appetite. Supplemental vitamins and minerals may support recovery. Antibiotics are not specifically indicated for PDNS itself but may be used to treat or prevent secondary bacterial infections in immunocompromised animals. Any medications used must be selected with attention to withdrawal times appropriate for the animal's market destiny. Treatment should be guided by ongoing assessment of response.

Surgical options are not applicable to PDNS management since the condition involves diffuse immune-mediated damage to kidneys and blood vessels rather than surgically correctable lesions. The role of the veterinarian in case management centers on accurate diagnosis, appropriate supportive care, guidance on prognosis, and humane euthanasia when indicated rather than surgical intervention.

Supportive care measures for PDNS cases include providing a quiet, comfortable environment with minimal stress from handling, mixing, or competition for resources. Hospital pens should have non-slip flooring and adequate bedding to prevent secondary injuries in weakened pigs. Water and feed should be positioned for easy access by animals reluctant to move. Environmental temperature should be maintained in the comfort zone, with supplemental heat for chilled pigs. Monitoring should track feed intake, body weight, attitude, and lesion progression to assess response and guide continued treatment versus euthanasia decisions.

Herd treatment protocols when multiple PDNS cases occur focus primarily on prevention in the broader population rather than treatment of affected individuals. Review of PCV2 vaccination protocols and timing ensures adequate protection. Identification and management of concurrent infections or stressors that may be triggering clinical disease expression guides intervention. Enhancement of general management practices including reduced stocking density, improved ventilation, and minimized mixing and movement stress reduces immune challenge. Individual clinically affected animals receive supportive care as described, but the primary emphasis shifts to preventing additional cases through population-level interventions.

Treatment decision factors in PDNS cases heavily weigh prognosis, which is guarded to poor for severely affected animals. Mildly affected pigs with limited skin lesions and minimal systemic illness may recover with supportive care and are worth treating. Severely ill pigs with widespread lesions, marked depression, significant weight loss, and evidence of advanced kidney failure are unlikely to respond to treatment and humane euthanasia is often the most appropriate option. The individual animal's value, available resources for nursing care, and potential for prolonged suffering guide the decision. Economic considerations in commercial operations typically favor early euthanasia of severely affected pigs rather than extended treatment with poor prognosis.

Recovery timeline for PDNS varies considerably based on case severity. Mildly affected pigs with limited skin lesions and relatively preserved kidney function may show improvement within one to two weeks of onset with supportive care, with skin lesions fading and appetite returning. Complete resolution may take three to four weeks or longer. More severely affected pigs that survive may require weeks to months for full recovery, and some may never return to normal kidney function. Permanent skin scarring at sites of severe lesions is possible. A significant proportion of clinically affected pigs, estimated at fifty percent or more, do not survive regardless of treatment efforts.

Post-treatment care and monitoring for PDNS survivors involves ongoing assessment of kidney function and general health. Serial blood chemistry helps track whether kidney parameters are normalizing or remaining elevated. Body weight monitoring ensures adequate growth and recovery of any weight lost during illness. Skin lesions should be monitored for resolution or scarring. Survivors should be protected from additional stressors that might trigger relapse or other manifestations of PCV2-associated disease. Long-term follow-up helps identify any animals with persistent kidney impairment that might affect future performance or suitability for various market destinations.

Prognosis factors for PDNS include the extent and severity of skin lesions, the degree of kidney dysfunction at presentation, the response to initial supportive care, and the presence of concurrent infections or complications. Pigs with limited lesions primarily on the hindquarters and relatively preserved appetite have better prognosis than those with widespread lesions and severe systemic illness. Early intervention before severe kidney failure develops improves outcomes. Animals showing improvement in attitude and appetite within the first few days of treatment have more favorable prognosis than those showing progressive deterioration. Concurrent diseases, particularly PRRS or other immunosuppressive conditions, worsen prognosis.

Return to production considerations for PDNS survivors depend on the extent of residual damage. Pigs that recover fully with normal kidney function and minimal scarring may return to normal growth and reach market weight without significant impact. Those with persistent kidney impairment may show reduced growth efficiency and may not reach expected market weight. Scarring from extensive skin lesions may cause condemnation or trimming at slaughter, reducing carcass value. Breeding animals that survive PDNS should be evaluated for residual kidney damage before return to production, as chronic kidney disease could affect reproductive performance and longevity. Generally, recovered animals are suitable for market completion but may not be ideal candidates for retention as replacement breeders.

Vaccination protocols are central to PDNS prevention since the condition is strongly associated with PCV2 infection. PCV2 vaccines have proven highly effective at reducing PCV2-associated diseases including PDNS when properly implemented. Vaccination timing is critical, with vaccines typically administered to piglets at three weeks of age or at weaning, timed to provide protection as maternal immunity wanes and before peak viral challenge occurs. Some operations use two-dose protocols for enhanced protection. Sow vaccination provides maternal antibody protection for young piglets and may reduce viral shedding in the breeding herd. Consistent vaccination of the entire population maintains herd immunity and reduces viral circulation.

Biosecurity measures for PDNS prevention focus on reducing PCV2 viral load and minimizing cofactors that trigger disease expression. Strict all-in/all-out flow by room or barn reduces viral buildup and prevents mixing of age groups. Thorough cleaning and disinfection between groups reduces environmental viral load. Preventing introduction of pigs from sources with unknown or poor PCV2 status protects naive herds. Quarantine of incoming animals with PCV2 vaccination before introduction reduces risk of introducing high viral loads. Rodent and bird control reduces potential mechanical vectors. Employee biosecurity prevents tracking virus between groups.

Nutritional prevention of PDNS involves ensuring optimal nutrition that supports immune function without predisposing to immune dysregulation. Diets should be balanced and appropriate for age and production stage. Adequate but not excessive protein intake supports immune function. Appropriate vitamin and mineral supplementation, particularly vitamins E and selenium that support immune health, may reduce susceptibility to immune-mediated diseases. Avoiding mycotoxin-contaminated feeds eliminates one potential cofactor for immune dysfunction. Consistent feed quality and appropriate feed transition protocols reduce stress that might trigger disease.

Management practices for PDNS prevention center on reducing immune stressors that trigger clinical disease in PCV2-infected pigs. Maintaining appropriate stocking density reduces disease transmission and stress. Optimizing ventilation provides good air quality and reduces respiratory disease pressure. Minimizing mixing of pigs from different sources reduces exposure to novel pathogens and social stress. Maintaining stable social groups after establishment reduces fighting and stress. Appropriate weaning age and practices reduce weaning stress. Controlling concurrent diseases, particularly PRRS, reduces immune challenge and cofactor effects.

Quarantine and testing protocols for PDNS prevention relate primarily to PCV2 status assessment and management. Incoming pigs should be quarantined and vaccinated for PCV2 before introduction to the main herd if vaccination status is unknown. Serological or PCR testing may help characterize PCV2 status of source herds when establishing new supplier relationships. Monitoring for clinical PDNS cases provides surveillance for disease expression that might indicate suboptimal control. Post-mortem examination of suspicious cases confirms diagnosis and maintains awareness. Regular review of PCV2 vaccination compliance and timing ensures protocol adherence.

Daily management and monitoring for PDNS prevention requires attention to pig health and recognition of early disease signs. Routine daily observation should note any pigs with skin lesions, depression, reduced appetite, or failure to thrive compared to pen mates. Early recognition of suspicious cases allows prompt isolation, diagnosis, and appropriate response. Regular review of mortality records and causes of death helps identify PDNS cases that might be missed during daily observation. Growth performance monitoring may reveal subclinical impacts of PCV2-associated disease even when classic PDNS cases are not observed. Staff training on recognition of PDNS signs enables early detection.

Housing and environmental management contribute significantly to PDNS prevention through optimization of conditions that reduce immune stress. Adequate floor space per pig reduces stress and disease transmission. Proper ventilation maintains air quality and controls temperature and humidity. Comfortable ambient temperatures reduce metabolic stress, with supplemental heat for young pigs and cooling for finishing pigs as needed. Clean, dry bedding reduces pathogen exposure and improves comfort. Separation of age groups prevents cross-infection between pigs at different stages of immunity. Hospital pens allow isolation and individual care of sick pigs.

Herd health programs for PDNS control should incorporate PCV2 management as a core component. Regular review of PCV2 vaccination protocols ensures timely and complete coverage. Monitoring for PCV2-associated diseases including PDNS, postweaning multisystemic wasting syndrome, and reproductive impacts provides surveillance for disease expression that might indicate control failures. Concurrent disease management, particularly PRRS control programs, addresses key cofactors. Working with veterinarians to develop comprehensive health programs that address multiple interacting disease challenges optimizes outcomes. Regular production benchmarking helps identify subclinical disease impacts.

Record keeping and monitoring systems should track PDNS cases and other PCV2-associated disease occurrences, including details of affected animals, clinical presentation, outcomes, and any concurrent conditions or potential triggers identified. Vaccination records should document compliance with protocols. Mortality records with diagnostic findings help characterize causes of death and identify trends. Production data including growth rates, feed efficiency, and mortality by age group may reveal PCV2 impacts even when specific diagnoses are not made. Integration of health and production records enables correlation of disease events with management factors.

Economic considerations for PDNS management favor investment in prevention through vaccination and management optimization. The cost of PCV2 vaccination is modest compared to losses from clinical disease, including direct mortality, reduced growth efficiency, and treatment costs. Comprehensive herd health programs that address PDNS as part of broader PCV2 and overall disease management provide return through improved productivity. Economic analysis of specific operations can quantify the value of PCV2 vaccination and guide decisions about program intensity. While PDNS case treatment is often unsuccessful, investment in good nursing facilities and protocols for mildly affected animals allows recovery of some pigs that would otherwise be lost.

High-risk breeds for PDNS have not been definitively identified, as the condition occurs across all commercial swine genetics. Some research has suggested variation in susceptibility to PCV2-associated diseases between genetic lines, but findings have not been consistent enough to clearly implicate specific breeds or lines. The sporadic nature of PDNS, with typically less than one percent of animals in affected herds developing the condition, makes identification of genetic risk factors challenging. Individual immune response variation likely influences which PCV2-infected pigs develop PDNS, and this variation has genetic components, but practical selection against susceptibility is not currently feasible.

Production type considerations for PDNS relate primarily to the age and management circumstances of different production phases rather than breed or type differences. Growing and finishing pigs in the eight to sixteen week age range face the highest risk regardless of genetic background, as this corresponds to the period of waning maternal immunity and active PCV2 infection. Pigs in operations with higher disease pressure from concurrent infections, suboptimal housing, or other stressors may face elevated risk. Breeding animals occasionally develop PDNS, including gilts in development units. All production stages and types should implement PCV2 vaccination and good management to minimize PDNS risk.

Genetic selection and testing for PDNS resistance is not currently practiced in commercial swine breeding programs. While research continues to explore genetic factors affecting immune response to PCV2 and susceptibility to associated diseases, no practical genetic tests or selection criteria for PDNS resistance are available. Selection programs appropriately focus on production traits, structural soundness, and overall disease resilience rather than specific resistance to this sporadically occurring syndrome. The most effective approaches to PDNS control remain vaccination and management optimization rather than genetic selection.

Commonly co-occurring conditions with PDNS relate primarily to the underlying PCV2 infection and immune dysregulation that characterize the disease. Postweaning multisystemic wasting syndrome, another PCV2-associated disease, may occur in the same herds or even the same animals, representing different manifestations of PCV2-related immunopathology. Porcine Reproductive and Respiratory Syndrome is frequently present as a concurrent infection and cofactor in herds experiencing PDNS. Bacterial infections secondary to immunosuppression, including respiratory infections and septicemia, may complicate PDNS cases. Enteritis from various causes may occur concurrently in immunocompromised pigs. The immune suppression associated with PCV2 predisposes to multiple secondary infections.

Conditions with similar symptoms to PDNS include other causes of skin lesions and kidney disease in pigs that must be differentiated. Erysipelas causes skin lesions but typically with diamond-shaped configuration, acute fever response, and antibiotic responsiveness. Classical swine fever and African swine fever are critical differential diagnoses that must be ruled out in any pig with hemorrhagic skin lesions, given their reportable status and economic impact potential. Porcine stress syndrome can cause skin discoloration and death but with different circumstances and presentation. Thrombocytopenic purpura causes hemorrhagic skin lesions from platelet deficiency. Drug reactions and other causes of vasculitis may mimic PDNS. Accurate diagnosis is essential given the different implications and management of these conditions.

Complications and sequelae of PDNS include death from kidney failure in severe cases, which occurs in a significant proportion of clinically affected pigs. Survivors may have chronic kidney disease with persistent impairment of kidney function affecting long-term productivity. Secondary bacterial infections may complicate the course of immunocompromised PDNS patients. Skin scarring at sites of severe lesions may cause cosmetic concerns and potential carcass trimming at slaughter. Overall immune compromise from PCV2-associated disease may predispose to other infections during and after the PDNS episode. Recovered animals should be monitored for long-term health impacts.